NCT04044781View on ClinicalTrials.gov

A Phase 1, Open-Label, PET Study of T2310 & BPN14770

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 10, 2020

Primary Completion Date

April 30, 2020

Study Completion Date

May 30, 2020

Conditions
To Determine Brain Target Occupancy of BPN14770
Interventions
DRUG

BPN14770, T2310

Subjects will be administered radio ligand T2310 and BPN14770 to determine brain occupancy of BPN14770.

Trial Locations (1)

10065

Weill Cornell Medicine, New York

Sponsors
All Listed Sponsors
lead

Tetra Discovery Partners

INDUSTRY

NCT04044781 - A Phase 1, Open-Label, PET Study of T2310 & BPN14770 | Biotech Hunter | Biotech Hunter